Dermata Therapeutics, Inc. — FY 2023 Form 10-K
Business context and period: This annual report covers the fiscal year ended December 31, 2023; it does not provide standalone fourth-quarter results. Dermata is a pre-revenue clinical-stage dermatology company developing products based on its freshwater-sponge technology. Its lead candidate, DMT310, is in Phase 3 development for acne; DMT410 is an earlier-stage topical botulinum-toxin delivery program.
Financial performance and position
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $4.07 million | $5.65 million |
| General and administrative expense | $3.97 million | $4.02 million |
| Total operating expenses | $8.04 million | $9.67 million |
| Net loss | $7.79 million | $9.61 million |
| Cash used in operating activities | $6.41 million | $8.83 million |
| Cash provided by financing activities | $7.61 million | $4.28 million |
Net loss improved by $1.82 million, reflecting lower operating expenses and higher interest income. R&D expense fell by $1.58 million, mainly due to lower clinical and nonclinical costs, partly offset by increased manufacturing preparation and personnel costs. G&A was essentially unchanged. No revenue means gross margin is not applicable; the filing provides no operating margin measure.
At year-end, cash and cash equivalents were $7.44 million, total assets $7.98 million, total liabilities $1.62 million, and stockholders’ equity $6.36 million. Current assets were approximately $7.98 million against current liabilities of $1.62 million; no debt balance is reported in the presented balance sheet. Accumulated deficit was $53.39 million. Management estimated cash would fund operations into the third quarter of 2024 and stated additional capital was required. Auditors reported substantial doubt about the company’s ability to continue as a going concern; management’s plans did not alleviate that doubt.
Material developments and outlook
- DMT310 acne: The company began enrolling in STAR-1, the first of two planned Phase 3 trials, in December 2023. Each study is expected to enroll about 550 patients and test weekly treatment for 12 weeks. Top-line STAR-1 results were expected in Q1 2025. The second Phase 3 study and long-term extension were subject to adequate financing; management targeted an NDA filing after successful trials and completion of required work.
- Earlier acne data: In the Phase 2b trial, DMT310 showed statistically significant improvements versus placebo in lesion counts and investigator assessment. At week 12, inflammatory lesions fell 62% versus 42% with placebo, and 44% versus 17% were investigator-assessment responders. These are earlier-stage results, not Phase 3 evidence.
- Other programs: DMT310 psoriasis development was on hold pending financing or a strategic partner. The rosacea study missed its primary endpoints and the company discontinued further investment in that indication. DMT410 produced positive proof-of-concept results in small, open-label trials, including a 75% average reduction in sweat production in a 10-patient hyperhidrosis trial; the company was seeking a botulinum-toxin partner for further studies.
- Funding and dilution: 2023 financing included common-stock/warrant offerings and a warrant inducement, producing $7.61 million net financing cash flow. At year-end, 8.36 million warrants were outstanding, with zero aggregate intrinsic value at the $0.61 closing share price. The November 2023 inducement generated about $2.0 million net proceeds and included new warrants subject to stockholder approval, which was obtained in January 2024. The filing reports 3.93 million common shares outstanding at year-end and 6.66 million as of March 18, 2024.
Risks, contingencies, and unusual items
- Financing and going concern: The company has no product revenue, expects continuing losses, and depends on additional financing or collaboration. Failure to raise funds could delay, reduce, or stop development. Equity financing may dilute holders; the auditors’ going-concern warning is a central risk.
- Supply and geopolitics: The only qualified source of Spongilla is a Russian supplier. The company said received shipments were sufficient for the planned acne Phase 3 program and NDA support, but sanctions, export controls, harvest conditions, or supply disruption could constrain further development or commercialization.
- Clinical and regulatory uncertainty: Phase 3 results may differ from Phase 2 findings. FDA may require additional evidence, including on whether hydrogen peroxide is merely a fluidizing agent, or request further studies. DMT310’s natural-source composition also creates manufacturing, quality-control, assay-development, and regulatory challenges.
- Intellectual property: Licensed DMT310 patents expired in 2022–2023; the company relies on pending newer applications, potential NCE exclusivity, supply arrangements, and trade secrets. Protection and exclusivity are uncertain.
- Nasdaq listing: Dermata received a minimum-bid-price deficiency notice in November 2023, with a compliance period through May 13, 2024. It could consider a reverse stock split; failure to regain compliance could lead to delisting.
- Unusual financing accounting: The November warrant inducement’s approximately $3.0 million incremental fair value was recorded as an equity issuance cost, rather than as an operating expense. A March 2023 warrant modification added approximately $0.1 million of equity issuance costs.
- Other: The company reported no material pending litigation. Management concluded disclosure controls and internal control over financial reporting were effective as of year-end; the external auditor did not provide an opinion on internal-control effectiveness.
Key facts investors should verify
- Cash, cash burn, financing activity, and updated runway after December 31, 2023, especially relative to the stated Q3 2024 cash estimate.
- Whether Dermata regained Nasdaq’s minimum-bid-price compliance by the deadline and whether a reverse split or other listing action occurred.
- STAR-1 enrollment, trial progress, funding for STAR-2 and the extension study, and any change to the Q1 2025 data timeline.
- Current share count, warrant terms and potential dilution, including the post-year-end warrant approvals and share issuances.
- Whether the Russian supply chain remains accessible and sufficient, and whether alternative sources have been qualified.
- Progress on DMT410 partnering and any concrete financing or strategic-partner support for psoriasis development.